A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515853-48-00

Acronym

MB12-C-02-24

Enrollment

269

Registered

2025-03-25

Start date

2025-09-05

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Croatia, Germany, Greece, Italy, Poland, Portugal, Romania, Slovakia, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026